ARHGEF4

Across TCGA pan-cancer cohorts, ARHGEF4 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ARHGEF4 data layer compared with 23 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ARHGEF4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ARHGEF4 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, GBM, and LSCC are the cancer types where ARHGEF4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.794	0.539	.002	27	view →
GBM	DFS	Median	All	0.228	0.506	.001	22	view →
LSCC	DFS	Quartile	II,III,IV	0.913	0.552	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ARHGEF4–HNSC (DFS)

Open the HNSC breakdown →